Compare Viatris Inc (VTRS) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs Weibo Corp — how do they compare? Viatris Inc trades at $16.45 (market cap $19.09B), while Weibo Corp trades at $6.64 (market cap $1.64B). The key difference: Viatris Inc is far larger — about 11.6× Weibo Corp's market cap, and Weibo Corp pays the higher dividend (9.11%). Which is the better fit depends on your goals.
| VTRS | WB | |
|---|---|---|
Market Cap | $19.09B | $1.64B |
Sector | Health | Media |
52-Week High | $17.86 | $12.83 |
52-Week Low | $9.49 | $6.63 |
Enterprise Value | $31.21B | $866.57M |
Dividend Yield | 2.89% | 9.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.
The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.
Weibo (WB) trades at $6.70, down 0.3% on the day, with mixed technical signals showing bearish moving averages but bullish oscillators. Fundamentally, the stock appears undervalued with a P/E of 5.53 and P/B of 0.41, while maintaining strong profitability with 73.36% gross margins and 17.78% net income margin. Recent Q2 2026 earnings beat expectations with $0.38 EPS versus $0.36 expected, though Q1 and Q4 2025 missed estimates.
The investment case balances deep value metrics against structural challenges. While the stock trades below book value and generates substantial cash flow, competitive pressures from Douyin and WeChat threaten long-term relevance. Analyst sentiment is divided with 41% buy ratings but 45% holds, reflecting uncertainty about growth visibility amid declining user metrics. The 8% dividend yield provides downside protection but may not offset fundamental erosion risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
